(ot) Awaiting 5 FDA approvals (Mcap 57 M )Low Float 2 MIL
GET IN NOW BEFORE THE STOCK GETS DISCOVERED !!!
This Unknown ULTRA LOW FLOAT Stock awaiting 5 FDA approvals and will rise to 7 by year end .IPCI has 15 Drugs in Pipeline many nearing ANDA/NDA filing including a potential Blockbuster .
Market Cap 57 Mil / Cash 8.5 M / Burn-rate 4.5 M per Year = Enough Cash until Profitability which will happen in 2012
First FDA approval and PartnerShip which is imminent will push this low float rocket into double digits easily ..GLTA
Market Cap: 57 M Cash: 8.5 M Price: 3.71 $
Shares Out: 15.9 Mil..(13 Mil Shares held by Insiders/Institutions) Low Float : 2 M
Intellipharmaceutics now has five ANDAs awaiting FDA approval with reported sales for branded and generic versions of these products being approximately $8 billion in 2010. The Company develops both ANDA product candidates and new drugs through the New Drug Application (NDA) 505(b)(2) regulatory pathway.
"The filing of a generic version of Seroquel XR® is one of the Company's performance milestones for 2011 and another important addition to our product portfolio filed for approval with the FDA, which includes generics of Focalin XR®, Effexor XR®, Protonix® DR and Glucophage® XR," commented Dr. Isa Odidi, CEO of Intellipharmaceutics. "These filings not only provide further validation of our Hypermatrix™ technology, they clearly demonstrate the flexibility of our technology to efficiently and effectively match a number of drug delivery profiles."